Key facts
- Pathalys Pharma’s last known valuation is $295.0M.
- It has raised $266.0M; the latest was Early Stage VC ($105.0M) in Aug 2024.
- Notable investors include KB Investment, OrbiMed, Samsara BioCapital, The Carlyle Group, Japan Post Investment — 12 tracked in total.
- Status: Privately Held (backing).
- ·The complete investor list — 12 names
- ·Watchlist + deal alerts for Pathalys Pharma
- ·The full record, as it builds
Funding rounds
No funding rounds for Pathalys Pharma are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Pathalys Pharma
Developer of advanced therapeutics designed to address unmet needs in the management of late-stage chronic kidney diseases. The company creates upacicalcet, which is a novel calcimimetic with the potential to improve the treatment of SHPT (secondary hyperparathyroidism) in hemodialysis patients by mimicking the action of calcium on tissues through the activation of the calcium-sensing receptor that is expressed in various human organ tissues, enabling healthcare companies to treat patients with end-stage critical kidney disease.
- Sector
- Healthcare
- HQ
- Raleigh, NC, United States
- Founded
- 2021
- Employees
- 8
- Website
- pathalys.com/
- Ownership
- Privately Held (backing)
Pathalys Pharma doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Pathalys Pharma shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Pathalys Pharma in its N-PORT filings yet. We sweep new filings monthly.